BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,349,000 | -24.9% | 63,893 | -9.9% | 0.02% | -17.4% |
| Q2 2023 | $5,788,000 | +0.2% | 70,903 | -8.9% | 0.02% | -4.2% |
| Q1 2023 | $5,774,000 | -16.1% | 77,829 | -6.2% | 0.02% | -20.0% |
| Q4 2022 | $6,878,000 | +17.9% | 82,985 | +304.1% | 0.03% | +15.4% |
| Q3 2022 | $5,833,000 | -17.3% | 20,537 | +0.9% | 0.03% | -13.3% |
| Q2 2022 | $7,057,000 | -23.5% | 20,357 | -4.5% | 0.03% | -9.1% |
| Q1 2022 | $9,230,000 | -25.6% | 21,314 | -11.1% | 0.03% | -21.4% |
| Q4 2021 | $12,404,000 | +13.5% | 23,977 | +6.3% | 0.04% | +7.7% |
| Q3 2021 | $10,933,000 | +6.9% | 22,562 | -0.6% | 0.04% | +8.3% |
| Q2 2021 | $10,223,000 | +26.5% | 22,705 | +7.3% | 0.04% | +12.5% |
| Q1 2021 | $8,082,000 | +32.2% | 21,160 | +9.9% | 0.03% | +18.5% |
| Q4 2020 | $6,115,000 | +60.3% | 19,256 | +25.1% | 0.03% | +28.6% |
| Q3 2020 | $3,814,000 | -37.9% | 15,394 | -33.8% | 0.02% | -40.0% |
| Q2 2020 | $6,140,000 | +85.1% | 23,252 | +32.9% | 0.04% | +52.2% |
| Q1 2020 | $3,317,000 | -55.1% | 17,491 | -48.0% | 0.02% | -39.5% |
| Q4 2019 | $7,390,000 | +104.4% | 33,668 | +82.2% | 0.04% | +100.0% |
| Q3 2019 | $3,615,000 | -32.1% | 18,476 | -27.6% | 0.02% | -34.5% |
| Q2 2019 | $5,322,000 | +121.8% | 25,528 | +111.2% | 0.03% | +123.1% |
| Q1 2019 | $2,399,000 | +28.4% | 12,085 | -6.4% | 0.01% | +18.2% |
| Q4 2018 | $1,868,000 | -74.5% | 12,909 | -64.0% | 0.01% | -69.4% |
| Q3 2018 | $7,314,000 | +3.3% | 35,833 | -25.1% | 0.04% | 0.0% |
| Q2 2018 | $7,081,000 | +6.3% | 47,861 | +8.5% | 0.04% | +2.9% |
| Q1 2018 | $6,663,000 | +4.8% | 44,117 | -10.1% | 0.04% | +12.9% |
| Q4 2017 | $6,357,000 | +7.2% | 49,070 | +0.0% | 0.03% | 0.0% |
| Q3 2017 | $5,932,000 | -49.1% | 49,069 | -50.5% | 0.03% | -3.1% |
| Q2 2017 | $11,652,000 | +142.9% | 99,170 | +110.2% | 0.03% | +18.5% |
| Q1 2017 | $4,797,000 | -3.9% | 47,190 | -0.1% | 0.03% | -3.6% |
| Q4 2016 | $4,992,000 | +6.8% | 47,227 | +10.7% | 0.03% | -3.4% |
| Q3 2016 | $4,672,000 | +0.9% | 42,664 | +3.9% | 0.03% | -3.3% |
| Q2 2016 | $4,630,000 | +24.1% | 41,060 | +4.1% | 0.03% | +20.0% |
| Q1 2016 | $3,730,000 | +1.1% | 39,460 | -3.7% | 0.02% | +8.7% |
| Q4 2015 | $3,688,000 | -20.4% | 40,973 | -18.3% | 0.02% | -20.7% |
| Q3 2015 | $4,636,000 | -9.5% | 50,143 | -3.6% | 0.03% | 0.0% |
| Q2 2015 | $5,123,000 | -5.3% | 52,029 | -3.6% | 0.03% | -6.5% |
| Q1 2015 | $5,412,000 | +10.0% | 53,966 | +1.3% | 0.03% | +6.9% |
| Q4 2014 | $4,922,000 | +11.6% | 53,273 | +13.0% | 0.03% | +11.5% |
| Q3 2014 | $4,411,000 | – | 47,146 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |